Clinical trial
A Non-randomized, Open-label, Dose-escalation Study to Evaluate the Safety, Tolerability, Kinetics and Efficacy of a Single Intravenous Infusion of ZS802 in Hemophilia A Subjects With Endogenous FVIII ≤2%.
NCT05523128 is registered in ClinicalTrials.gov with Institute of Hematology & Blood Diseases Hospital, China as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Non-randomized, Open-label, Dose-escalation Study to Evaluate the Safety, Tolerability, Kinetics and Efficacy of a Single Intravenous Infusion of ZS802 in Hemophilia A Subjects With Endogenous FVIII ≤2%.
- Lead sponsor
- Institute of Hematology & Blood Diseases Hospital, China
- Phase
- Not applicable
- Overall status
- Unknown status
- Start date
- September 29, 2022
- Completion date
- October 31, 2025
- Enrollment
- 6 (estimated)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.